Maria Camila Escobar Garcia

Dr. Maria Camila Escobar Garcia


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
FSFrancisca Hildemagna Guedes da Silva
Francisca Hildemagna Guedes da Silva
VPVictor Augusto Augusto Roncaglia Roncaglia Pereira
Victor Augusto Augusto Roncaglia Roncaglia Pereira
STSara Torres
Sara Torres
MGMaria Camila Escobar Garcia
Maria Camila Escobar Garcia
KVKelvinson Fernandes Viana
Kelvinson Fernandes Viana
AGAndre Gomes
Andre Gomes
Throughout human history, contagious infectious diseases have significantly impacted societies, shaping the fate of great dynasties and challenging economic and political systems, social relations, and the overall well-being of the human species. The SARS-CoV-2 pandemic brought unprecedented challenges, emerging in the context of extreme globalization and rapid technological development. The speed of viral spread, the highest absolute mortality rate caused by a viral agent in the last 100 years, and the severe economic and social consequences imposed an urgent need for vaccine development on a previously unimaginable timescale. The proven safety and efficacy of inactivated vaccines enabled the development and large-scale application of the first immunizer against SARS-CoV-2 in less than a year after the World Health Organization (WHO) declared the pandemic. In this review, we discuss the importance of inactivated antiviral vaccines and their historical impact in containing highly harmful diseases affecting humanity. We also explore the cellular mechanisms by which inactivated vaccines may induce immunogenic responses against viral pathogens. In addition, we bring to light a discussion about a fast, cost-effective, potentially efficient technology for large-scale immunizer production: High hydrostatic pressure (HHP), a method long supported by decades of preclinical studies and which is especially effective in the context of enveloped viruses. Finally, we discuss the role of inactivated antiviral vaccines in the face of advances in biotechnology and, therefore, the emergence of vaccines that use genetic engineering in their production, such as RNA, DNA and viral vaccines, which have gained special prominence during the COVID-19 pandemic.

1 September 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
KVKelvinson Fernandes Viana
Kelvinson Fernandes Viana
ASAdrieli Barboza de Souza
Adrieli Barboza de Souza
STSara Torres
Sara Torres
MGMaria Camila Escobar Garcia
Maria Camila Escobar Garcia
ARAçucena Veleh Rivas
Açucena Veleh Rivas
RODOLFO CORDEIRO GIUNCHETTIRODOLFO CORDEIRO GIUNCHETTI
RODOLFO CORDEIRO GIUNCHETTI
Background/Objectives: Canine visceral leishmaniasis (CVL) is one of the main neglected protozoan diseases in the world. Dogs play a fundamental role in the maintenance of Leishmania infantum in the Americas, and we have already encountered resistance problems with drugs currently used in these animals. Methods: In view of this, two new immunotherapeutic protocols were tested in 48 dogs, using L. amazonensis antigens plus saponin (LaSap) and only L. amazonensis antigens (La) as a control group. Dogs naturally infected with L. infantum were divided into four groups, according to clinical staging. A total of 24 dogs (stages 1 and 2) received a four-dose protocol, and another 24 dogs (stages 3 to 5) received six doses. All animals received a booster dose every three months until they were one year old. Results: Our results showed that dogs in the early stages of the disease respond better and are able to remain stable for longer, maintaining baseline laboratory biomarkers, in addition to having a lower parasite load. Conclusions: On the other hand, dogs in more advanced stages have a poor response, with stage 3 being a key point in clinical progression or regression.